DZ2383A1 - Procédé pour la cristallisation d'un dérivé de tétrahydropyridine et formes cristallines ainsi obtenues - Google Patents

Procédé pour la cristallisation d'un dérivé de tétrahydropyridine et formes cristallines ainsi obtenues

Info

Publication number
DZ2383A1
DZ2383A1 DZ970233A DZ970233A DZ2383A1 DZ 2383 A1 DZ2383 A1 DZ 2383A1 DZ 970233 A DZ970233 A DZ 970233A DZ 970233 A DZ970233 A DZ 970233A DZ 2383 A1 DZ2383 A1 DZ 2383A1
Authority
DZ
Algeria
Prior art keywords
crystallization
crystalline forms
tetrahydropyridine derivative
tetrahydropyridine
derivative
Prior art date
Application number
DZ970233A
Other languages
English (en)
French (fr)
Inventor
Antoine Caron
Bruno Franc
Olivier Monnier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DZ2383A1 publication Critical patent/DZ2383A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DZ970233A 1996-12-23 1997-12-22 Procédé pour la cristallisation d'un dérivé de tétrahydropyridine et formes cristallines ainsi obtenues DZ2383A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (1)

Publication Number Publication Date
DZ2383A1 true DZ2383A1 (fr) 2002-12-28

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970233A DZ2383A1 (fr) 1996-12-23 1997-12-22 Procédé pour la cristallisation d'un dérivé de tétrahydropyridine et formes cristallines ainsi obtenues

Country Status (39)

Country Link
EP (1) EP0950050B1 (zh)
JP (2) JP4499188B2 (zh)
KR (1) KR100586670B1 (zh)
CN (1) CN1129580C (zh)
AR (1) AR009672A1 (zh)
AT (1) ATE307802T1 (zh)
AU (1) AU736697B2 (zh)
BR (1) BR9714081A (zh)
CA (1) CA2275596C (zh)
CO (1) CO5070688A1 (zh)
CZ (1) CZ296689B6 (zh)
DE (1) DE69734460T2 (zh)
DK (1) DK0950050T3 (zh)
DZ (1) DZ2383A1 (zh)
EE (1) EE04188B1 (zh)
EG (1) EG21567A (zh)
ES (1) ES2251038T3 (zh)
FR (1) FR2757543B1 (zh)
HK (1) HK1024002A1 (zh)
HR (1) HRP970699B1 (zh)
HU (1) HU227425B1 (zh)
IL (1) IL129938A (zh)
IN (1) IN186976B (zh)
IS (1) IS2357B (zh)
MY (1) MY118015A (zh)
NO (1) NO312364B1 (zh)
NZ (1) NZ336130A (zh)
PL (1) PL190494B1 (zh)
RS (1) RS49882B (zh)
RU (1) RU2192416C2 (zh)
SA (1) SA98180971B1 (zh)
SI (1) SI0950050T1 (zh)
SK (1) SK285088B6 (zh)
TR (1) TR199901363T2 (zh)
TW (1) TW518322B (zh)
UA (1) UA60324C2 (zh)
UY (1) UY24825A1 (zh)
WO (1) WO1998028271A1 (zh)
ZA (1) ZA9711576B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
WO2011111857A1 (ja) 2010-03-12 2011-09-15 株式会社日本触媒 吸水性樹脂の製造方法
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
HUP0001387A3 (en) 2002-03-28
CZ296689B6 (cs) 2006-05-17
KR100586670B1 (ko) 2006-06-07
CN1129580C (zh) 2003-12-03
DK0950050T3 (da) 2006-01-23
JP2001507012A (ja) 2001-05-29
RS49882B (sr) 2008-08-07
ZA9711576B (en) 1998-06-25
JP2009197022A (ja) 2009-09-03
EE9900264A (et) 2000-02-15
ES2251038T3 (es) 2006-04-16
YU28999A (sh) 2003-01-31
AR009672A1 (es) 2000-04-26
UA60324C2 (uk) 2003-10-15
HUP0001387A2 (hu) 2000-09-28
CA2275596C (en) 2005-10-11
DE69734460D1 (de) 2005-12-01
EE04188B1 (et) 2003-12-15
SK82899A3 (en) 1999-12-10
IS2357B (is) 2008-04-15
PL190494B1 (pl) 2005-12-30
HRP970699B1 (en) 2007-03-31
NO312364B1 (no) 2002-04-29
HU227425B1 (en) 2011-05-30
ATE307802T1 (de) 2005-11-15
FR2757543B1 (fr) 1999-04-02
MY118015A (en) 2004-08-30
IN186976B (zh) 2001-12-22
NO993076D0 (no) 1999-06-22
SA98180971B1 (ar) 2006-09-13
HRP970699A2 (en) 1998-10-31
EP0950050B1 (fr) 2005-10-26
CO5070688A1 (es) 2001-08-28
CZ229299A3 (cs) 1999-09-15
FR2757543A1 (fr) 1998-06-26
SK285088B6 (sk) 2006-06-01
AU5668498A (en) 1998-07-17
DE69734460T2 (de) 2006-07-06
KR20000069504A (ko) 2000-11-25
BR9714081A (pt) 2000-05-09
IS5076A (is) 1999-06-10
IL129938A (en) 2004-06-20
EP0950050A1 (fr) 1999-10-20
IL129938A0 (en) 2000-02-29
PL334256A1 (en) 2000-02-14
NO993076L (no) 1999-06-22
TW518322B (en) 2003-01-21
TR199901363T2 (xx) 1999-08-23
HK1024002A1 (en) 2000-09-29
NZ336130A (en) 2001-01-26
UY24825A1 (es) 1998-04-21
RU2192416C2 (ru) 2002-11-10
CA2275596A1 (en) 1998-07-02
WO1998028271A1 (fr) 1998-07-02
SI0950050T1 (sl) 2006-04-30
JP4499188B2 (ja) 2010-07-07
AU736697B2 (en) 2001-08-02
CN1241180A (zh) 2000-01-12
EG21567A (en) 2001-12-31

Similar Documents

Publication Publication Date Title
FR2744010B1 (fr) Procede de fabrication d'implants osseux
FR2708601B1 (fr) Procédé de cristallisation d'Iopamidol.
DZ2032A1 (fr) Un procédé pour la préparation de l'hydrochlorure de lercanidipine.
MA23179A1 (fr) Procede de preparation d'un monohydrate cristallin d'un spirostanylglycoside
FR2764883B1 (fr) Procede de fabrication d'hydrofluoroalcanes
FR2743808B1 (fr) Procede de preparation de chlorures d'alkyle
DZ2383A1 (fr) Procédé pour la cristallisation d'un dérivé de tétrahydropyridine et formes cristallines ainsi obtenues
MA24534A1 (fr) Procede pour la production d'irones
FR2754816B1 (fr) Procede de purification d'hydrogenochlorofluoroethanes
DZ3074A1 (fr) Formes cristallines du (R)-(+)-N-Ä3-Ä1 berizoyl-3-(3,4-dichlorophényl)pipéridin-3YLÜpropyl-1-YLÜ-4-phénylpipéridin-4-YLÜ-N-méthylacetamide(osanétant) et procédé pour leur préparation.
FR2633290B1 (fr) Procede pour la fabrication de carbamates d'iodoalcynyles
MA23081A1 (fr) Procede de preparation de derives d'indolone
FR2755238B1 (fr) Procede de caracterisation d'un photorepeteur
FR2644161B1 (fr) Procede de preparation d'amides n-arylsubstitues
FR2729387B1 (fr) Procede pour la fabrication d'hydroxy-alcoxy-benzophenones
FR2602766B1 (fr) Composes dichlorotrifluoromethylnitrotoluenes et procede de preparation d'aminotrifluoromethyltoluenes a partir de ces composes
NO308471B1 (no) FremgangsmÕter for fremstilling av lorakarbefmonohydrat og krystallinsk anhydratform av lorakarbef
FR2615185B1 (fr) Procede de preparation de trifluoromethyltoluene a partir d'halomethylbenzotrifluorure
FR2732154B1 (fr) Procede de fabrication d'isolateurs
FR2757510B1 (fr) Forme microparticulaire d'un derive de tetrahydropyridine
MA23986A1 (fr) Procede de preparation d'hydrates de phosphate trisodique cristallins
MA24258A1 (fr) Procede de monoacylation d'hydoxytaxanes
FR2723293B1 (fr) Procede pour la realisation d'une confiserie de type touron
FR2742431B1 (fr) Procede d'elaboration de granulats de construction a partir de machefers
FR2712214B1 (fr) Procédé de cristallisation des déchets.